Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lauren Baloy

Nurse Practitioner Longmont, CO Nurse Practitioner

NPI 1871000638 CMS profile 10516850

1925 Mountain View Ave Fl 3, Longmont, CO 80501

Open in the dashboard

General payments

$146

3 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lauren Baloy of Longmont, CO is reported in the CMS Open Payments database as having received $146 across 3 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 33rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $32 1
2022 General $99 1
2021 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Baloy
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Lauren Baloy were reported at $32. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Lauren Baloy Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $15 $135 $40–$426 $132
2022 $99 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $32 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Endogastric Solutions, Inc $99 1 payment
  2. Genzyme Corporation $32 1 payment
  3. Takeda Pharmaceuticals U.S.A., Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $146 3 payments
Products named General payments · program years 2021–2025
  1. EsophyX $99 1 payment
  2. DUPIXENT $32 1 payment
  3. MOTEGRITY $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,316

Median for Nurse Practitioner: 389

Drug cost

$259,346

Median for Nurse Practitioner: $21,885

Branded share of claims

18.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 29 $107,089
Linzess Linaclotide Brand 101 $69,893
Mesalamine Generic 36 $20,726
Dexlansoprazole Dr Dexlansoprazole Brand 40 $17,314
Trulance Plecanatide Brand 14 $8,011
Omeprazole Generic 341 $6,706
Colesevelam Hcl Generic 16 $5,804
Famotidine Generic 272 $5,425
Pantoprazole Sodium Generic 257 $4,361
Lubiprostone Generic 22 $2,873

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$41,883

Medicare's payments for the services billed

Medicare patients

304

Average age 73

Services billed

1,473

202 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 47%
Ischemic heart disease 28%
Diabetes 26%
Depression 26%
Chronic kidney disease 21%
Osteoporosis 18%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record